Advanced Cell Technology (ACT) has treated the final patient in the UK-based Phase 1 clinical trial evaluating the safety and tolerability of the company’s stem cell therapy for Stargardt’s disease. To date, no adverse events have been reported. The company is working with U.S. and European regulators to commence a Phase 2 trial to assess the safety and efficacy of stem cell therapy in patients with Stargardt disease and dry age-related macular degeneration.
Read the company’s press release for more information.
